Amundi Novo Cure LTD Transaction History

Amundi

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $667,800 - $946,800	60,000 New	60,000 $895,000
Q2 2023 Aug 14, 2023	SELL	$40.29 - $82.51 $5.67 Million - $11.6 Million	-140,754 Reduced 63.2%	81,944 $3.4 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $1.07 Million - $2.25 Million	18,929 Added 9.29%	222,698 $13.4 Million
Q4 2022 Feb 14, 2023	BUY	$63.98 - $85.37 $1.23 Million - $1.64 Million	19,184 Added 10.39%	203,769 $14.9 Million
Q3 2022 Nov 14, 2022	BUY	$67.99 - $89.57 $1.61 Million - $2.12 Million	23,618 Added 14.67%	184,585 $15.7 Million
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $4.5 Million - $7.15 Million	79,567 Added 97.75%	160,967 $11.7 Million
Q1 2022 May 16, 2022	BUY	$60.15 - $84.52 $573,109 - $805,306	9,528 Added 13.26%	81,400 $7 Million
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $213,377 - $346,695	2,842 Added 4.12%	71,872 $5.01 Million
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $1.39 Million - $2.32 Million	11,940 Added 20.91%	69,030 $8.02 Million
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $7.44 Million - $12.9 Million	57,090 New	57,090 $12.7 Million

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.77B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Amundi, based on Form 13F filings with the SEC.

Stay updated on Amundi with notifications on news.